CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03111732
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:23.184988+00:00
- Published At
- 2021-04-15T00:00:00+00:00
- Record Updated At
- 2021-12-03
- Results Posted At
- 2021-04-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Biliary Tract Neoplasms", "Cholangiocarcinoma", "Bile Duct Cancer", "Liver Cancer", "Gallbladder Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-12-03"- protocolSection.identificationModule.nctId
"NCT03111732"- protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-04-15"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.